Researchers engineered Bifidobacterium bacteria to produce thymosin alpha-1, creating an oral delivery system that successfully stimulated T cell growth and immune function in mice. After oral administration, treated mice showed increased T cell populations, elevated immune-boosting cytokines, and enlarged thymus and lymph nodes, offering a more convenient alternative to injection-based thymosin alpha-1 therapy.
Shao, Congwen; Tian, Guojun; Huang, Yuanjian; Liang, Wenying; Zheng, Hang; Wei, Jiannan; Wei, Cheng; Yang, Cuilan; Wang, Hong; Zeng, Weisen